RGX 014
Alternative Names: RGX-014Latest Information Update: 27 Mar 2023
At a glance
- Originator Rgenix
- Developer Inspirna
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Mar 2023 Discontinued for Cancer in USA (Parenteral) (Inspirna pipeline, March 2023)
- 30 Sep 2021 Rgenix is now called Inspirna
- 28 Jul 2020 No recent reports of development identified for research development in Cancer in USA